+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France

  • ID: 2559792
  • Report
  • April 2019
  • Region: France
  • 141 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France

Summary

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in France. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of France. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by a team of industry experts.

In 2010, the French pharmaceutical market was worth $36.5B, which decreased to an estimated $33.5B in 2017 at a negative Compound Annual Growth Rate (CAGR) of 1.5%. The French medical devices market was valued at $17.7B in 2015, which increased to $19B in 2017. The market is expected to grow at a CAGR of 4% from $19.7B in 2018 to $21.2B in 2020. Regulatory reforms have led to faster and more efficient drug approval processes. The French healthcare system provides universal health coverage, healthcare reimbursement, and open healthcare access with implementation of E-health card for the French people.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the France, and includes -
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Sanofi, Servier, Pierre Fabre and Ipsen) and profiles and SWOT analyses of the major players in the medical device market (Roche, Medtronic, Abbott, Siemens and Boston Scientific)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of France
  • Porter’s five forces analysis for pharmaceutical and medical devices market of France
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the French healthcare market.
Reasons to Buy

The report provides information on the healthcare, regulatory, and reimbursement landscape in the France, and includes -
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Sanofi, Servier, Pierre Fabre and Ipsen) and profiles and SWOT analyses of the major players in the medical device market (Roche, Medtronic, Abbott, Siemens and Boston Scientific)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of France
  • Porter’s five forces analysis for pharmaceutical and medical devices market of France
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the French healthcare market.
Note: Product cover images may vary from those shown
2 of 3
  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter’s Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges
  • Appendix
List of Tables
  • Table 1: Pharmaceutical Market, France, Sales of Patented Drug Products by Major Therapeutic Class at Ex factory Prices (%), 2017
  • Table 2: Medical Device Market, France, Revenue by Segment ($B), 2017
  • Table 3: IVD Market, France, Revenue ($M) and Market Share (%) of Major Companies
  • Table 4: Cardiovascular Devices , France, Revenue ($M) and Market Share (%) of Major Companies
  • Table 5: Hospital Supplies Market, France, Revenue ($M) and Market Share (%) of Major Companies
  • Table 6: Orthopedic Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies
  • Table 7: Ophthalmic Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies
  • Table 8: Actual Clinical Benefit (ACB), France, 2018
  • Table 9: Clinical Added Value (CAV), France, 2018
  • Table 10: Rreimbursement Rates for Medical Procedures and Services Covered by Health Insurance Schemes, France, 2019
  • Table 11: Pricing Based on ASMR Level, France, 2018
  • Table 12: Patent Fees, France, 2018
  • Table 13: Trademark Fees, France, 2018
  • Table 14: Label of a Pharmaceutical Product, France, 2017
  • Table 15: Minimum particulars to appear on blisters or strips , France, 2017
  • Table 16: Minimum particulars to appear on small immediate packaging , France, 2017
List of Figures
  • Figure 1: Pharmaceutical Market, France, Revenue ($B), 2010-2017
  • Figure 2: Medical Device Market, France, Revenue ($B), 2015-2020
  • Figure 3: Number of Deals (2018-2019)
  • Figure 4: 2018-19 Deal Overview By Region
  • Figure 5: Country Profile, France, 2018
  • Figure 6: Pharmaceutical Market, France, Revenue ($B), 2010-2017
  • Figure 7: Pharmaceutical Market, France, Revenue Forecast ($B), 2018-2022
  • Figure 8: Pharmaceutical Market, France, Pharmaceutical Exports
  • Figure 9: Pharmaceutical Market, France, Top Export Partners
  • Figure 10: Pharmaceutical Market, France, Pharmaceutical Imports
  • Figure 11: Pharmaceutical Market, France, Top Import Partners
  • Figure 12: Marketing Authorizations for Generic Medicines, France, 2012-2017
  • Figure 13: Availability of Biologics in Healthcare Settings, France, 2017
  • Figure 14: Competitiveness Clusters , France, 2017
  • Figure 15: Government Funded Biosimilars, France, 2017
  • Figure 16: Pharmaceutical OTC Market, France, Revenue ($B), 2010-2017
  • Figure 17: Major OTC Drug Classes (Share%), France, 2017
  • Figure 18: Pharmaceutical Market, France, Supply Channels
  • Figure 19: Pharmaceutical Market, France, Sales of Patented Drug Products by Major Therapeutic Class at Ex factory Prices (%), 2017
  • Figure 20: Pharmaceutical Market, Major Players, France
  • Figure 21: Medical Device Market, France, Revenue ($B), 2015-2020
  • Figure 22: Medical Device Market, France, Revenue Forecast ($B), 2021-2025
  • Figure 23: Medical Device Market, France, Revenue by Segment ($B), 2018
  • Figure 24: IVD Market, France, Revenue ($B), 2015-2022
  • Figure 25: IVD Market, France, Market Share of Major Players (%)
  • Figure 26: Cardiovascular Devices Market, France, Revenue ($B), 2015-2022
  • Figure 27: Cardiovascular Devices Market, France, Market Share of Major Players (%)
  • Figure 28: Hospital Supplies, France, Revenue ($B), 2015-2022
  • Figure 29: Hospital Supplies, France, Market Share of Major Players (%)
  • Figure 30: Orthopedic Market, France, Revenue ($B), 2015-2022
  • Figure 31: Orthopedic Devices Market, France, Market Share of Major Players (%)
  • Figure 32: Ophthalmic Devices Market, France, Revenue ($B), 2015-2022
  • Figure 33: Ophthalmic Devices Market, France, Market Share of Major Players (%)
  • Figure 34: Diagnostic Market, France, Revenue ($B), 2015-2018
  • Figure 35:Diagnostic Market, France, Revenue Forecast ($B), 2019-2022
  • Figure 36: Medical Device Market - Major Players
  • Figure 37: Deal Value and Deal Count, Pharmaceutical Market, France, 2018-2019
  • Figure 38: Deal Value and Deal Count Quarterly, Pharmaceutical Market, France, 2018-2019
  • Figure 39: Deal Value and Deal Count Sub-Types, Pharmaceutical Market, France, 2018-2019
  • Figure 40: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, France, 2018-2019
  • Figure 41: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, France, 2018-2019
  • Figure 42: M&A Deals by Therapy Area, Pharmaceutical Market, France, 2018-2019(by value and by number)
  • Figure 43: Venture Financing Deals by Therapy Area, Pharmaceutical Market France, 2018-2019(by value and by number)
  • Figure 44: Private Equity Deals by Therapy Area, Pharmaceutical Market France, 2018-2019(by value and by number)
  • Figure 45: Medical Device Market Deals, France, 2018-2019(by deal value, $M)
  • Figure 46: Medical Device Market Deals, France, 2018 -2019(by deal count)
  • Figure 47: Medical Device Market Deals Share (by deal count), France, 2018 - 2019
  • Figure 48: Medical Device Market Deals Share (by deal value), France, 2018 - 2019
  • Figure 49: Top Five Therapy Areas by Deal Value, Medical Device, France, 2018-2019
  • Figure 50: Top Five Therapy Areas by Deal Number, Medical Device, France, 2018-2019
  • Figure 51: M&A Deals by Therapy Area, Medical Device, France, 2018-2019 (by number)
  • Figure 52: Venture Financing Deals by Therapy Area, Medical Device, France, 2018-2019(by value and by number)
  • Figure 53: Private Equity Deals by Therapy Area, Medical Device France, 2018-2019(By number)
  • Figure 54: Healthcare System, France, 2018
  • Figure 55: Workflow of Healthcare System, France, 2018
  • Figure 56: Medicine Assessment Process, France, 2018
  • Figure 57: Medical Device Assessment Process, France, 2018
  • Figure 58: Network of Public Insurance Providers, France, 2018
  • Figure 59: Revenue Structure of CNAM, France, 2017
  • Figure 60: Funding by Mutuals, France, 2018
  • Figure 61: Funding by Provident Institutions, France, 2018
  • Figure 62: Funding by Insurance Companies, France, 2018
  • Figure 63: OOP Expenditure (% of total expenditure on health), France, 2010-2016
  • Figure 64: Annual Rate of Change (%), Health Price Index, France, 2010-2019
  • Figure 65: Pricing Process, France, 2019
  • Figure 66: The Evolution of the Price of Drugs, France, 2018
  • Figure 67: ANSM, Organizational Structure, France, 2019
  • Figure 68: National Procedure, France, 2017
  • Figure 69: Centralized Procedure, 2018
  • Figure 70: Decentralized Procedure, 2018
  • Figure 71: Mutual Recognition Procedure, 2018
  • Figure 72: Conformity Assessment of Class I Medical Devices, EU, 2018
Note: Product cover images may vary from those shown
3 of 3
France has a mature healthcare market, based on its high healthcare expenditure and pharmaceutical production. The increasingly elderly population is expected to drive the growth of the pharmaceutical market; however, an increasing focus on generics to reduce healthcare expenditure will balance this out.

The French pharmaceutical market was valued at $48.9 billion in 2008 and an estimated $45.9 billion in 2013. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 0.7% from approximately $46.2 billion in 2014 to $48.2 billion in 2020.

The public health insurance system was established in 1945, and by 2011, approximately 97% of the population was covered under Statutory Health Insurance (SHI), divided into three main schemes: general, agriculture, and non-salaried and non-farming (World Bank, 2014p). This universal healthcare coverage is expected to continue to drive the French pharmaceutical market. The increasingly elderly population is also fueling pharmaceutical market growth, accounting for 17.6% of the total population in 2013 and expected to increase at a CAGR of 1.5% to 19.7% by 2020 (INSEE, 2014f).

The government is focusing on the use of generics as a cost-containment tool to reduce healthcare expenditure. It introduced a scheme in September 2012 to increase the use of generic drugs, under which patients who agree to generic substitution will not be required to pay for their drugs. The substitution rate increased from 71% to 84% in one year as a result: a cost saving of approximately €200m ($270m) (Thomson, et al., 2013). In 2008, generic drugs accounted for 9.4% of the pharmaceutical market in terms of value and 21.7% in terms of volume, increasing to an estimated 15.3% and 27.7% respectively in 2013 (ANSM, 2013). However, this is expected to act as a barrier to the growth of the pharmaceutical market.

The French medical device market was valued at $12.7 billion, which increased to $15.5 billion in 2013. It is projected to grow at a CAGR of 5.1% from $16.2 billion in 2014 to $21.8 billion in 2020. In 2013, In Vitro Diagnostics (IVD) accounted for 15.3% of the overall medical device market, followed by cardiovascular devices (11.4%), ophthalmic devices (10.7%), orthopedic devices (8.4%) and hospital supplies (7.4%).
Note: Product cover images may vary from those shown
Adroll
adroll